---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-166293"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:35:32.098180+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management

## Summary
- Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.
- ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.
- Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.
- Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.
- Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories.

## SEC filing metadata
- accession: 0001193125-24-166293
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/0001193125-24-166293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/d841207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-166293
- JSON: https://secwatch.observer/filing/0001193125-24-166293.json
- Plain text: https://secwatch.observer/filing/0001193125-24-166293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.